Tag: Announces

Pikes Peak Historical Society announces online auction | Pikes Peak Courier

Each fall, the Pikes Peak Historical Society holds an auction as its major fundraising event of the year. This year, due to Covid restrictions, the auction is being conducted online. The auction will go live on the PPHS website, pikespeakhsmuseum.org, just look for the auction icon that will take you to the auction site. Once there, everything is self-explanatory.

“We are looking for services, gift certificates, trips, guided tours, handmade quilts, craft items, artwork, and cash donations are always welcome,” said Kathy Perry, an event organizer.

Incorporated in 1988, PPHS is among the largest nonprofits in Teller County, with almost 500 members. Over 99% of the annual revenue is applied toward the museums and various programs.

PPHS owns and operates two museums: The Pikes Peak Historical Society Museum, at 18033 Teller County Road 1 across from the Florissant Post Office; and the Schoolhouse Museum located at Teller County Road 31 and Wildhorn. PPHS volunteers also manage the historic Florissant cemetery on behalf of Teller County and present free educational programs.

The organization installed sandstone signs for the town of Florissant and built an informational kiosk on the east side of town. All programs are done without taxpayer money. They are funded by donations, memberships, grants and the generosity of citizens.

With pandemic concerns, they have been unable to reopen the museums, but the cost of upkeep continues, which is why it was decided to hold the annual auction on line.

The auction will go live Oct. 23 to view all items. Bidding will begin at 10 a.m. Oct. 24 and run through 7 p.m. Oct. 28.

Source Article

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per share on October 2, 2020.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Mesoblast securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005438/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

Source Article

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Precigen, Inc. (PGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Precigen, Inc. (“Precigen” or the “Company”) (NASDAQ: PGEN) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 25, 2020, the U.S. Securities and Exchange Commission (“SEC”) announced a $2.6 million civil penalty against the Company related to its statements about the “purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (‘MBC’) program.” In its cease-and-desist order, the SEC noted that “Intrexon was primarily using significantly more expensive pure methane for the relevant laboratory experiments but was indicating that the results had been achieved using natural gas.” Though the Company had pitched the program to business partners throughout 2017 and 2018, the SEC pointed out that a “number of the potential partners performed due diligence on the MBC program including reviewing lab results and plans for commercialization[, and] Intrexon has not yet found a partner for the MBC program.”

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Precigen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201002005459/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

Source Article

Continue reading

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF will be presented at the upcoming Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting to be held September 30, – October 6. Scheduling details and registration information are provided below:

Title:

 

Levosimendan Improves Hemodynamics and Submaximal Exercise Capacity In PH-HFpEF: Primary Results From The HELP-PH-HFpEF Multicenter Randomized Controlled Trial

 

 

Speaker:

 

Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic

 

 

Session:

 

Late-Breaking Clinical Trials I (LBCT I)

 

 

Date/Time:

 

Saturday, October 3, 4:30 – 5:30 PM

   

Registration and additional HFSA information are available at the HFSA website: https://hfsa.org/hfsa-announces-late-breaking-clinical-trials-sessions-hfsa-virtual-asm-2020.

Tenax CEO Anthony DiTonno stated, “We are very excited to have the HELP Study results presented as a late-breaking clinical trial at the HFSA Annual Meeting. We believe the results may represent a potential advance in the treatment of PH-HFpEF patients who currently have no FDA-approved therapies to treat their condition. We look forward to having the detailed trial results presented at this major scientific forum.”

About Phase 2 HELP Trial

The HELP Study (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) was a multi-center, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate levosimendan in 36 patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Endpoints in the trial evaluated various invasive hemodynamic and clinical measures including a 6-minute walk test. The Company previously announced positive topline results from this Phase 2 trial. The trial demonstrated significant reduction in right atrial and pulmonary capillary wedge pressures. It also demonstrated a significant improvement with 6-minute walk distance.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. The forward-looking statements are subject

Continue reading

SECAF Announces 12th Annual Government Contractor Award Winners

GovCon Community Comes Together Virtually to Mark Excellence and Celebrate Success

The Small and Emerging Contractors Advisory Forum (SECAF) is pleased to announce the winners of the 12th Annual Government Contractor Awards. Last night hundreds of people representing government contracting firms and leading industry professionals gathered virtually as the 2020 winners were named. More than 40 regional business leaders chose this year’s finalists from an exemplary group of applicants. Award winners were then selected by a distinguished group of judges, including Shiv Krishnan (CEO, KOOLROX and Founder of INDUS Corp), Kevin Robbins (Co-Founder of Blue Delta Capital Partners and Co-Founder of Wolf Den Associates), Peter Schulte (Principal, CM Equity), and Eric Wolking (Operating Partners, Bluestone Investment Partners). The Event Chairs were Scott Brezler (Managing Partner – Government Contracting Industry Group, DHG), Cameron Hamilton (Managing Director, FON Corporate Finance), and Adam Nalls (Senior Vice President, Atlantic Union Bank).

The Government Contractor of the Year awards recognize companies in four revenue categories (Under $7.5M, $7.5-15M, $15-27.5M, and $27.5-50M) that have shown a compelling and profound commitment to excellence in growth and financial performance. The Award of Excellence highlights an organization that represents excellence within their community, the government contracting industry, and towards employees. The Government Project of the Year is given to a company that has delivered a stellar program with significant value to the federal government. The Mentor-Protégé Program of the Year honors companies that have shown a compelling and profound commitment to excellence through its efforts as a prime contractor.

The Special Recognition Award is presented to a small business that – in the judges’ view – exemplifies many of the core qualities of the other SECAF awards and has a strong focus on providing class-leading services and solutions. The Government Advocate of the Year commends an organization or a person within the federal government who has provided leadership, commitment, and direction and had a profound and positive impact on the small and emerging contracting community. The Executive of the Year is new for 2020 and represents a regionally-based individual that has shown a compelling and profound commitment to excellence to their company, within the community, the government contracting industry, and towards their employees. Finally, the SECAF Advocate of the Year is bestowed upon a member who has tirelessly championed the organization’s mission.

This year’s winners are as follows:

Government Contractor of the Year: Under $7.5 Million in Revenue

Government Contractor of the Year: $7.5 to $15 Million in Revenue

Government Contractor of the Year: $15 to $27.5 Million in Revenue

Government Contractor of the Year: $27.5 to $50 Million in Revenue

Award of Excellence

Government Project of the Year

Mentor-Protégé Program of the Year

Special Recognition Award

Government Advocate of the Year

Executive of the Year

SECAF Advocate of the Year

For more than a decade, SECAF’s flagship event has honored small and emerging government contractors by recognizing the key role these firms have in creating innovation and advancement within their industry.

More information about the

Continue reading

Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology Society of North America (RSNA) 2020

Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology
Society of North America (RSNA) 2020

NEVE ILAN,  Israel, Oct.  01,  2020 (GLOBE  NEWSWIRE)  -- NANO-X  IMAGING  LTD
(NASDAQ: NNOX)  (“Nanox”  or the  “Company”),  an innovative  medical  imaging
technology company, is pleased to announce today that it will demonstrate  its
novel technology (Nanox.SOURCE) and medical imaging system (Nanox.ARC) at RSNA
2020, which is being held November 29-December 5 in Chicago.

The demonstration will  include a  technology section  elaborating on  Nanox’s
first commercial-grade digital x-ray source  followed by a live  demonstration
of the Nanox.ARC in a range of 2D and 3D medical imaging procedures.

The demonstration  will  be led  by  Mr.  Ran Poliakine,  Chairman  and  Chief
Executive Officer  of Nanox,  and  will be  live  streamed globally.  It  will
include  a  professional  radiology  Q&A  session  followed  by  lectures  and
presentations of clinical applications of the Nanox.ARC medical imaging system
by well-known radiologists and Company distribution partners.

Mr. Poliakine stated: “We are pleased to invite everyone to witness first-hand
our technology and the  Nanox.ARC at the  RSNA. We have  an ambitious goal  of
making  medical  imaging  widely  available  on  a  global  basis  to  promote
preventive healthcare  through  early  detection. Two-thirds  of  the  world’s
population currently have no access to medical imaging, and we aim to  improve
this statistic. We look forward to this demonstration which will allow  people
to see the depth and validity of our technology.”

About Nanox:

Nanox, founded  by  the  serial  entrepreneur Ran  Poliakine,  is  an  Israeli
corporation  that  is  developing  a  commercial-grade  digital  X-ray  source
designed to be used in real-world medical imaging applications. Nanox believes
that its  novel technology  could significantly  reduce the  costs of  medical
imaging systems and plans to seek collaborations with world-leading healthcare
organizations and  companies to  provide affordable,  early detection  imaging
service for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to
risks and uncertainties. All statements that are not historical facts
contained in this press release are forward-looking statements. Such
statements include, but are not limited to, any statements relating to the
initiation, timing, progress and results of Nanox's research and development,
manufacturing and commercialization activities with respect to its X-ray
source technology and the Nanox.ARC. In some cases, you can identify
forward-looking statements by terminology such as “can,” “might,” “believe,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“should,” “could,” “expect,” “predict,” “potential,” or the negative of these
terms or other similar expressions. Forward-looking statements are based on
information Nanox has when those statements are made or management's good
faith belief as of that time with respect to future events, and are subject to
risks and uncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the forward-looking
statements. Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to business interruptions
resulting from the COVID-19 pandemic or similar public health crises could
cause a disruption of the 
Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Fulton Financial Corporation (FULT) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Fulton Financial Corporation (“Fulton” or the “Company”) (NASDAQ: FULT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 28, 2020, the U.S. Securities and Exchange Commission (“SEC”) announced that Fulton had been charged with accounting and disclosure violations. Specifically, the SEC stated that, in two quarters in which Fulton was on track to meet or beat analyst consensus EPS estimates, Fulton included a valuation allowance that “was at odds” with its reported methodology. Then, in mid-2017, “Fulton belatedly reversed the valuation allowance, increasing its EPS by a penny in a quarter when it otherwise would have fallen short of consensus estimates.”

On this news, the Company’s share price fell sharply during intraday trading on September 29, 2020.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Fulton securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001006222/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

Source Article

Continue reading

American Cancer Society Announces Drive-Thru Fundraiser At Jones Beach, Long Island’s Largest Breast Cancer Awareness Event Adjusts To Pandemic

NEW YORK (CBSNewYork) – Thursday marks the beginning of Breast Cancer Awareness Month.

The usual fundraising events, like breast cancer walks, are going to be much different this year. In fact, as CBS2’s Dr. Max Gomez reports, one of Long Island’s biggest fundraisers has become a drive-thru event.

Breast cancer awareness is critical every year and every month, of course. But, many women have been putting off their mammograms, or even cancer treatments, due to the coronavirus pandemic.

Cancer doesn’t wait. So, this year, awareness and action are even more important.

The American Cancer Society’s Making Strides of Long Island cancer walks, said to be the largest in the country, have been held annually in October at Jones Beach.

But, these kinds of mass gatherings, especially for cancer patients and survivors, are simply off limits during the pandemic.

RELATED STORY: Doctors Urge Women To Get Breast Screenings Now, Don’t Wait For Pandemic To End

Long Island elected officials, spokeswomen for the American Cancer Society and survivors gathered to make sure breast cancer awareness stays top of mind this month.

“I just want to thank the American Cancer Society for all the things that they’re doing, for having my back and my front in so many ways throughout my fight over the past 16 months,” said Adina Perullo, a breast cancer survivor.

The most interesting announcement: this year’s Making Strides fundraiser will be a drive-thru event.

The fully in-car, rolling pep rally at Jones Beach will be fully compliant with COVID-19 safety guidelines. But, you must make reservations online, ahead of time, for a timeslot on October 18 from 7 a.m. to 2 p.m.

LINK: CLICK HERE for more information about this year’s Making Strides event at Jones Beach.

For the top questions people have been asking about the coronavirus, visit cbsnewyork.com/max, and go to facebook.com/cbsnewyork to submit your question.

You can get the latest news, sports and weather on our brand new CBS New York app. Download here.

Continue Reading

Source Article

Continue reading

Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology Society of North …

NEVE ILAN, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, is pleased to announce today that it will demonstrate its novel technology (Nanox.SOURCE) and medical imaging system (Nanox.ARC) at RSNA 2020, which is being held November 29-December 5 in Chicago.

The demonstration will include a technology section elaborating on Nanox’s first commercial-grade digital x-ray source followed by a live demonstration of the Nanox.ARC in a range of 2D and 3D medical imaging procedures.

The demonstration will be led by Mr. Ran Poliakine, Chairman and Chief Executive Officer of Nanox, and will be live streamed globally. It will include a professional radiology Q&A session followed by lectures and presentations of clinical applications of the Nanox.ARC medical imaging system by well-known radiologists and Company distribution partners.

Mr. Poliakine stated: “We are pleased to invite everyone to witness first-hand our technology and the Nanox.ARC at the RSNA. We have an ambitious goal of making medical imaging widely available on a global basis to promote preventive healthcare through early detection. Two-thirds of the world’s population currently have no access to medical imaging, and we aim to improve this statistic. We look forward to this demonstration which will allow people to see the depth and validity of our technology.”

About Nanox:

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox’s

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of HP Inc. (HPQ) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of HP Inc. (“HP” or the “Company”) (NYSE: HPQ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 30, 2020, the U.S. Securities and Exchange Commission (“SEC”) announced that HP had agreed to pay $6 million to settle charges “for misleading investors by failing to disclose the impact of sales practices undertaken in an effort to meet quarterly sales and earnings targets.” The SEC’s Order stated that, from early 2015 through mid-2016, “in an effort to meet quarterly sales targets, regional managers at HP used a variety of incentives to accelerate, or “pull-in” to the current quarter, sales of printing supplies that they otherwise expected to materialize in later quarters.”

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased HP securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005519/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

Source Article

Continue reading